Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains
暂无分享,去创建一个
[1] B. Garcia,et al. Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. , 2014, Blood.
[2] Feng Zhang,et al. Genome engineering using CRISPR-Cas9 system. , 2015, Methods in molecular biology.
[3] E. Lander,et al. Development and Applications of CRISPR-Cas 9 for Genome Engineering , 2015 .
[4] Meagan E. Sullender,et al. Rational design of highly active sgRNAs for CRISPR-Cas9–mediated gene inactivation , 2014, Nature Biotechnology.
[5] Jay Shendure,et al. Saturation Editing of Genomic Regions by Multiplex Homology-Directed Repair , 2014, Nature.
[6] Junwei Shi,et al. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. , 2014, Molecular cell.
[7] E. Lander,et al. Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.
[8] Shiyou Zhu,et al. High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells , 2014, Nature.
[9] Yilong Li,et al. Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library , 2013, Nature Biotechnology.
[10] J. Krosl,et al. The methyltransferase G9a regulates HoxA9-dependent transcription in AML , 2014, Genes & development.
[11] Neville E. Sanjana,et al. Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.
[12] E. Lander,et al. Genetic Screens in Human Cells Using the CRISPR-Cas9 System , 2013, Science.
[13] Ming Yu,et al. Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation , 2013, Genes & development.
[14] David A. Scott,et al. Genome engineering using the CRISPR-Cas9 system , 2013, Nature Protocols.
[15] Eli J. Fine,et al. DNA targeting specificity of RNA-guided Cas9 nucleases , 2013, Nature Biotechnology.
[16] S. Orkin,et al. Targeted Disruption of the EZH2/EED Complex Inhibits EZH2-dependent Cancer , 2013, Nature chemical biology.
[17] James E. DiCarlo,et al. RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.
[18] R. Roeder,et al. Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia , 2013, Proceedings of the National Academy of Sciences.
[19] S. Lowe,et al. The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;NrasG12D acute myeloid leukemia , 2013, Oncogene.
[20] Le Cong,et al. Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.
[21] S. Orkin,et al. Targeted Disruption of the EZH 2 / EED Complex Inhibits EZH 2-dependent Cancer , 2013 .
[22] J. Doudna,et al. A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.
[23] Crispin J. Miller,et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. , 2012, Cancer cell.
[24] S. Lowe,et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.
[25] S. Robson,et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.
[26] P. Sandy,et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains , 2011, Proceedings of the National Academy of Sciences.
[27] Yonghong Xiao,et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. , 2011, Cancer cell.
[28] S. Lowe,et al. Reversible suppression of an essential gene in adult mice using transgenic RNA interference , 2011, Proceedings of the National Academy of Sciences.
[29] Christof Fellmann,et al. Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi , 2011, Nature Biotechnology.
[30] T. Kitamura,et al. Plat-E: an efficient and stable system for transient packaging of retroviruses , 2000, Gene Therapy.